EPHA5 and cancer: We designed, generated, and developed MBRC-101, a first-in-class targeted ADC against EphA5, and conducted a comprehensive preclinical program of efficacy and Good Laboratory Practice (GLP) toxicology to support investigational testing in human patients with cancer.